BNT317 / BioNTech - LARVOL DELTA

BNT317: an anti–PD-1 × CD39 bispecific antibody demonstrating preclinical antitumor activity (ESMO 2026) - No abstract available

Bispecific • Preclinical • Oncology • ENTPD1

BNT317-01: Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=248 | Recruiting | Sponsor: BioNTech SE | Phase classification: P1 ➔ P1/2 | N=39 ➔ 248 | Trial completion date: Jun 2028 ➔ Apr 2031 | Trial primary completion date: Jun 2028 ➔ Apr 2031

Enrollment change • First-in-human • Phase classification • Trial completion date • Trial primary completion date • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • EGFR • HER-2

Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=39 | Recruiting | Sponsor: BioNTech SE | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor